Univariate analysis of patient, donor, and transplantation characteristics and subsequent development of H–Y antibodies
. | ≥1 H–Y antibody detected . | . | . | ||
|---|---|---|---|---|---|
| Transplantation characteristics . | Yes n = 39 (%) . | No n = 36 (%) . | P . | ||
| Primary disease | .64* | ||||
| Acute myeloid leukemia | 9 | 8 | |||
| Acute lymphoblastic leukemia | 4 | 4 | |||
| Chronic myeloid leukemia | 11 | 8 | |||
| Chronic lymphocytic leukemia | 3 | 2 | |||
| Myelodysplastic syndrome | 5 | 6 | |||
| Non-Hodgkin lymphoma | 4 | 6 | |||
| Hodgkin disease | 2 | 0 | |||
| Multiple myeloma | 1 | 1 | |||
| Other | 0 | 1 | |||
| Good prognosis | >.99 | ||||
| Yes | 16 (41) | 15 (42) | |||
| No | 23 (59) | 21 (58) | |||
| Patient age | .69 | ||||
| Median (range), y | 45 (19-59) | 44 (19-66) | |||
| Donor age | .58 | ||||
| Median (range), y | 39 (16-69) | 39 (14-69) | |||
| HSC donor | .06† | ||||
| HLA-matched related | 29 (74) | 19 (53) | |||
| HLA-matched unrelated | 6 (15) | 13 (36) | |||
| HLA-mismatched related | 1 (3) | 2 (6) | |||
| HLA-mismatched unrelated | 3 (8) | 2 (6) | |||
| HSC source | .82 | ||||
| Bone marrow | 22 (56) | 22 (61) | |||
| Peripheral blood stem cells | 17 (44) | 14 (39) | |||
| Stem cell processing | .39 | ||||
| Unmanipulated | 33 (85) | 27 (75) | |||
| T-cell depleted | 6 (15) | 9 (25) | |||
| Conditioning regimen | .61 | ||||
| Myeloablative | 29 (74) | 24 (67) | |||
| Nonmyeloablative | 10 (26) | 12 (33) | |||
. | ≥1 H–Y antibody detected . | . | . | ||
|---|---|---|---|---|---|
| Transplantation characteristics . | Yes n = 39 (%) . | No n = 36 (%) . | P . | ||
| Primary disease | .64* | ||||
| Acute myeloid leukemia | 9 | 8 | |||
| Acute lymphoblastic leukemia | 4 | 4 | |||
| Chronic myeloid leukemia | 11 | 8 | |||
| Chronic lymphocytic leukemia | 3 | 2 | |||
| Myelodysplastic syndrome | 5 | 6 | |||
| Non-Hodgkin lymphoma | 4 | 6 | |||
| Hodgkin disease | 2 | 0 | |||
| Multiple myeloma | 1 | 1 | |||
| Other | 0 | 1 | |||
| Good prognosis | >.99 | ||||
| Yes | 16 (41) | 15 (42) | |||
| No | 23 (59) | 21 (58) | |||
| Patient age | .69 | ||||
| Median (range), y | 45 (19-59) | 44 (19-66) | |||
| Donor age | .58 | ||||
| Median (range), y | 39 (16-69) | 39 (14-69) | |||
| HSC donor | .06† | ||||
| HLA-matched related | 29 (74) | 19 (53) | |||
| HLA-matched unrelated | 6 (15) | 13 (36) | |||
| HLA-mismatched related | 1 (3) | 2 (6) | |||
| HLA-mismatched unrelated | 3 (8) | 2 (6) | |||
| HSC source | .82 | ||||
| Bone marrow | 22 (56) | 22 (61) | |||
| Peripheral blood stem cells | 17 (44) | 14 (39) | |||
| Stem cell processing | .39 | ||||
| Unmanipulated | 33 (85) | 27 (75) | |||
| T-cell depleted | 6 (15) | 9 (25) | |||
| Conditioning regimen | .61 | ||||
| Myeloablative | 29 (74) | 24 (67) | |||
| Nonmyeloablative | 10 (26) | 12 (33) | |||